Atossa reports Q3 2026 results, outlines CVR tied to future priority review voucher
Atossa says it expects FDA clearance of its DMD and McCune-Albright Syndrome IND applications for (Z)-endoxifen in early 2027, with Phase 2 trials to follow.
SEC filing